Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial

6533b859fe1ef96bd12b7758

RESEARCH PRODUCT

Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial

Georg Mann Anne Uyttebroeck Denise Williams Wilhelm Woessmann Emanuele S.g. D'amore Christine Damm-welk Elisa Carraro Atsuko Nakazawa Suzanne D. Turner Suzanne D. Turner Auke Beishuizen Rafael Fernández-delgado Fernández-delgado Cerdá Birgit Burkhardt Marie-cécile Le Deley Andishe Attarbaschi Monika Csóka Lara Mussolin Laurence Brugières Amos Burke Wolfram Klapper Alfred Reiter Keizo Horibe Laurence Lamant Karin Mellgren Grażyna Wróbel

subject

MDD 0301 basic medicine Oncology Cancer Research medicine.medical_specialty Multivariate analysis IMPACT BONE-MARROW FEATURES CHILDREN long-term follow-up lcsh:RC254-282 Article DISEASE CLASSIFICATION Childhood Anaplastic Large Cell Lymphoma 03 medical and health sciences 0302 clinical medicine Internal medicine ADOLESCENTS medicine VINBLASTINE Progression-free survival Young adult Pathological Anaplastic large-cell lymphoma childhood Science & Technology business.industry Hazard ratio CHEMOTHERAPY lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease ALCL ALCL; MDD; childhood; long-term follow-up 030104 developmental biology Oncology 030220 oncology & carcinogenesis Minimal Disseminated Disease NON-HODGKIN-LYMPHOMA business Life Sciences & Biomedicine

description

With the aim of describing the long-term follow-up and to define the prognostic role of the clinical/pathological/molecular characteristics at diagnosis for childhood, adolescent and young adults affected by anaplastic large cell lymphoma (ALCL), we analyzed 420 patients aged up to 22 years homogeneously treated within the international ALCL99 trial. The 10-year progression free survival (PFS) was 70% and overall survival was 90%, rare late relapses occurred but no secondary malignancies were reported. Among clinical/pathological characteristics, only patients presenting a small cell/lymphohistiocytic (SC/LH) pattern were independently associated with risk of failure (hazard ratio = 2.49). Analysis of minimal disseminated disease (MDD), available for 162 patients, showed that both SC/LH pattern (hazard ratio = 2.4) and MDD positivity (hazard ratio = 2.15) were significantly associated with risk of failure in multivariate analysis. Considering MDD and SC/LH results, patients were separated into three biological/pathological (bp) risk groups: a high-risk group (bpHR) including MDD-positive patients with SC/LH pattern

year	journal	country	edition	language
2020-09-24	Cancers

https://doi.org/10.3390/cancers12102747